Project overview
This prospective study compared low-dose mifepristone (5 mg/day) and the levonorgestrel intrauterine system (LNG-IUS) in 74 premenopausal women with symptomatic adenomyosis over six months. Both treatments led to significant reductions in uterine volume, menstrual blood loss, and dysmenorrhea, with no statistically significant difference between groups at the study's conclusion. While LNG-IUS showed a faster initial reduction in bleeding, both therapies achieved similar improvements in hemoglobin levels and quality of life. Adverse effects were mild in both arms, with only one case of device expulsion. These findings suggest that both low-dose mifepristone and LNG-IUS are safe, effective, and conservative options for adenomyosis management.
This summary describes the research topic in our project library. Research findings belong to the authors; they are not outcomes of editorial support. Authors retain responsibility for their work.
Back to this project’s library page